BioLargo’s price and value potential remain unchanged from prior analyses.
The recent rise in BioLargo’s stock value is closely linked to the EPA. Consequently, enhanced PFAS regulatory measures are potentially affecting the water treatment sector and indicating BioLargo’s expansion in U.S. municipal water systems.
BioLargo Inc Stock Price Today | OTC BLGO Live Ticker – Investing.com
BioLargo’s Market Movements and PFAS Roadmap
BioLargo, Inc. (OTCQB: $BLGO) has witnessed a notable surge in its share price over the past month. This uptick is a strong indicator of the company’s potential expansion into thousands of U.S. municipal drinking water systems. This development comes as the U.S. Environmental Protection Agency (EPA) advances its initiatives under the PFAS Roadmap.
The recent legislation has almost entirely banned over 300 PFAS chemicals in manufacturing. Additionally, there have been updates to the Toxic Release Inventory (TRI) disclosure requirements. These developments hint at more comprehensive guidance and broader legislation expected in 2024.
Implications of PFAS Legislation on Industry
Designating PFOA and PFOS (PFAS) as Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA) hazardous substances will require published releases of these chemicals that meet or exceed the reportable quantity assigned to these substances.
In summary, final designation was originally expected in March 2024 with statutory implementation occurring no later than September 2024. This has some municipal water systems gravely concerned about high operational costs associated with adequate PFAS detection, let alone removal and disposal.
Regardless, the EPA’s tightening of continued PFAS production represents momentum to carry its multiyear initiative to complete fruition, costs be damned.
EPA’s Testing Thresholds and Industry Response
Several officials affiliated with the EPA’s PFAS Strategic Roadmap admit desired testing thresholds of 4 parts-per-trillion may change to a more detectable-yet-feasibly-safe level. Until detection technologies improve in both efficacy and cost.
For perspective, 4 parts per trillion (4ppt) is roughly the equivalent of a single drop of PFAS in a volume of water that equates to about five Olympic-sized swimming pools, or approximately 3,302,150 gallons.
Ultimately, more information on PFAS, including updated on EPA’s progress can be found here. Agilent Technologies (NYSE: $A) and Waters Corporation (NYSE: $WAT) represent two distinguished partners specializing in application-focused diagnostics and high-performance liquid chromatography (HPLC) and mass spectrometry (MS) technology systems, respectively.
BioLargo’s Strategic Positioning
BioLargo’s ongoing partnership with ICS Group since 2021 will enable the company’s proprietary PFAS AEC removal and disposal technology to attract substantial operating contracts.
As a matter of fact, largely subsidized U.S. EPA monies as a bipartisan crusade to ensure improved potable drinking water remains a top legislative priority. In effect receiving little to no political resistance.
To conclude, with more global manufacturing and industrial companies assuming record PFAS-disposal related fines, in addition to issuing moratoriums on further PFAS production. Ultimately, companies as those listed herein stand to benefit in both the short- and long-term horizon. As more PFAS guidance and legislative progress becomes public, BioLargo will certainly be the primary corporate beneficiary.
Understanding PFAS
PFAS, or per- and polyfluorinated alkyl substances, are a group of chemicals historically used in products like nonstick coatings and water-resistant fabrics.
However, their persistence and potential health risks, including a heightened risk of certain cancers, have led to increased regulatory scrutiny.
These ‘forever chemicals’ are known for their durability and tendency to accumulate in the human body over time.
Additional Resources
For more in-depth information on PFAS and related topics, including previous coverage on EPA Accelerates PFAS Roadmap; BioLargo, Inc. to Benefit (tradersque.com).
Further commentary and insights are available on the author’s LinkedIn page at http://tinyurl.com/4yz9t2c2.
